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Adoptive T-cell therapy using tumor-infiltrating lympho-
cytes (TIL) has emerged as a powerful salvage therapy
option for patients with metastatic melanoma, even those
that have progressed on anti-CTLA-4 and anti-PD-1 pro-
tocols. The expansion of TIL enriched in effector-memory
CD8+ T cells with demonstrated anti-tumor activity is cri-
tical in mediating durable clinical responses to TIL ther-
apy. However, the current methods to expand TIL from
melanoma tumors were not designed to facilitate the rapid
and selective outgrowth of this critical CD8+ T-cell sub-
population. This has required cumbersome selection tech-
niques applied to early stage TIL cultures involving unreli-
able in vitro assays measuring IFN-gamma secretion in
response to autologus or HLA-matched tumor cell lines.
Selected early stage TIL lines are then further expanded to
generate the final infusion product. Thus, a practical
method to selectively expand tumor-specific CD8+ T cells
from tumor fragments in situ would be a great asset. In
this study, we capitalized on the ability of tumor-infiltrat-
ing CD8+ T cells to express the TNF-R family member
co-stimulatory molecule 4-1BB in response to antigenic
stimulation. We found that a fraction of TIL present in
freshly-isolated melanoma metastases expressed 4-1BB, a
sign of recent activation. Remarkably, we found that addi-
tion of an agonistic anti-4-1BB to cultures of tumor frag-
ments from these melanoma lesions promoted early TIL
outgrowth and dramatically increased the rate of CD8+
TIL expansion. These accelerated CD8+ TIL-enriched
products also exhibited a much higher degree of tumor
specificity, as determined in both IFN-gamma secretion
and CTL assays using tumor targets. TIL initially
expanded from tumor fragments with anti-4-1BB also had
increased a more optimal effector-memory phenotype for
adoptive transfer, including higher cytolytic granule and
anti-apoptotic gene expression. Our findings suggest that
4-1BB agonists can be provided immediately during the
initiation of TIL growth from tumors to develop a stream-
lined and practical system to accelerate the expansion of
more highly tumor-specific CD8+ T cells. This approach
would avoid the unreliable and cumbersome selection pro-
tocols for tumor-specificity needed for current TIL proto-
cols and would facilitate the industrialization of TIL
therapy.
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